Geoff von Maltzahn, Tessera Therapeutics CEO
Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing
A few years ago, the gene editing approach at Tessera was just a “twinkle in our eye,” CEO and co-founder Geoff von Maltzahn said. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
